ARTICLE | Distillery Therapeutics

Therapeutics: CC chemokine receptor 5 (CCR5; CD195)

January 8, 2015 8:00 AM UTC

Mouse studies suggest CCR5 antagonists could help prevent prostate cancer metastasis. In mouse models of metastatic prostate cancer, the CCR5 antagonist Selzentry maraviroc decreased metastatic burden by 80% in bone and 60% in brain compared with vehicle. Next steps could include planning a clinical trial to evaluate marketed CCR5 antagonists in prostate cancer patients.

Pfizer Inc. and GlaxoSmithKline plc market Selzentry to treat HIV / AIDS...